Skip to main content
Enwei Pharmaceutical Co., Ltd. logo

Enwei Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 301331 ISIN · CNE100005LC7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2023-04-21 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 301331

About Enwei Pharmaceutical Co., Ltd.

https://www.enwei.com.cn

Enwei Pharmaceutical Co., Ltd. focuses on the research, development, and manufacturing of medicinal products, specializing in Chinese patent medicines and chemical drugs. The company is primarily known for its gynecological health solutions, most notably the Jie Er Yin brand. Its diverse product range covers therapeutic categories such as pediatrics, dermatology, and respiratory care. By combining traditional Chinese medicine with modern pharmacological standards, the company produces various dosage forms including lotions, capsules, and granules. The organization emphasizes clinical efficacy and quality management, targeting a wide range of healthcare needs through ongoing innovation in formulation and drug delivery systems.

Recent filings

Filing Released Lang Actions
独立董事关于第二届董事会第十二次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors providing prior approval opinions on matters to be discussed at the company's second board of directors' twelfth meeting. It includes opinions on the proposal to reappoint the 2023 financial audit firm and on the expected 2023 related party transactions. The document is not a full audit report but rather an independent directors' approval statement related to board meeting agenda items. It does not contain financial statements or detailed audit results, nor is it a general announcement or a report publication notice. This type of document fits best under Board/Management Information (MANG), as it relates to board meeting matters and independent directors' opinions on governance and audit firm reappointment.
2023-04-21 Chinese
信永中和会计师事务所（特殊普通合伙）关于恩威医药2022年度非经营性资金占用及其他关联资金往来的专项说明
Audit Report / Information Classification · 95% confidence The document is titled as a "专项说明" (special explanation) regarding "非经营性资金占用及其他关联资金往来" (non-operating fund occupation and other related party fund transactions) for the year 2022 of 恩威医药股份有限公司. It includes a summary table of related party fund transactions and is prepared in accordance with regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange. The document is signed by a certified public accounting firm and references the audited financial statements for 2022, but it is not the full annual report or audit report itself. It is a specialized disclosure related to regulatory compliance about related party transactions, which is typical of an Audit Report / Information filing that supplements the annual financial statements but is not the full annual report (10-K). The document length (7482 characters) and content indicate it is a standalone audit-related disclosure rather than a full annual report or a simple announcement. Therefore, the most appropriate classification is Audit Report / Information (AR). FY 2022
2023-04-21 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Enwei Pharmaceutical Co., Ltd. It details the approval of various reports and proposals related to the 2022 fiscal year and the first quarter of 2023, including the 2022 Supervisory Board Work Report, 2022 Financial Final Accounts Report, 2022 Annual Report and its summary, 2022 Profit Distribution Plan, appointment of the 2023 audit firm, 2022 Internal Control Self-Evaluation Report, and the 2023 Q1 Report. The document is a formal announcement of the Supervisory Board's meeting decisions and approvals, not the reports themselves. It also states that these reports and proposals will be submitted to the 2022 Annual General Meeting for further approval. The document length is 2743 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is an official announcement of meeting resolutions and approvals related to various reports, not the reports themselves.
2023-04-21 Chinese
信永中和会计师事务所（特殊普通合伙）关于恩威医药2022年12月31日内部控制鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制鉴证报告" which translates to "Internal Control Assurance Report" and includes detailed internal control self-evaluation and assurance related to the company's financial reporting for the year ended December 31, 2022. It is issued by an accounting firm and addresses the effectiveness of internal controls related to financial statements. The content includes evaluation of internal control environment, risk assessment, control activities, information and communication, and internal supervision. It does not contain full financial statements or comprehensive annual financial performance data, but rather focuses on internal control audit and assurance. This matches the description of an Audit Report / Information (AR) which includes standalone audit reports and applied accounting principles related to internal controls. The document length is 8646 characters, which is sufficient for a detailed audit report. Therefore, the appropriate classification is AR with high confidence. FY 2022
2023-04-21 Chinese
2022年年度报告摘要
Annual Report Classification · 95% confidence The document is titled '2022 年年度报告摘要' which translates to '2022 Annual Report Summary'. It contains detailed financial data for the year 2022, including total assets, net profit, revenue, and quarterly financial data. It also includes company business descriptions, shareholder information, and auditor opinions. The presence of comprehensive financial statements and business overview indicates this is a full annual report or a summary thereof. The document length is over 11,000 characters, which is substantial and not a mere announcement or notice. Therefore, this document fits the definition of an Annual Report (10-K). FY 2022
2023-04-21 Chinese
2022年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled as the "2022年度监事会工作报告" which translates to "2022 Supervisory Board Work Report". It details the supervisory board's activities, meetings, oversight on financials, internal controls, related party transactions, and governance for the year 2022. It is a comprehensive report on the supervisory board's work rather than a full annual report or audit report. The document contains substantive content about the supervisory board's oversight and plans for 2023, indicating it is a management or supervisory report rather than a simple announcement or certification. Given the nature of the content focusing on management's explanation and oversight of financial and operational matters, the best fitting category is Management Reports (MDA).
2023-04-21 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.